Giannis Mountzios

6.3k total citations · 3 hit papers
124 papers, 3.2k citations indexed

About

Giannis Mountzios is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Giannis Mountzios has authored 124 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Oncology, 65 papers in Pulmonary and Respiratory Medicine and 33 papers in Molecular Biology. Recurrent topics in Giannis Mountzios's work include Lung Cancer Treatments and Mutations (56 papers), Lung Cancer Research Studies (31 papers) and Cancer Immunotherapy and Biomarkers (22 papers). Giannis Mountzios is often cited by papers focused on Lung Cancer Treatments and Mutations (56 papers), Lung Cancer Research Studies (31 papers) and Cancer Immunotherapy and Biomarkers (22 papers). Giannis Mountzios collaborates with scholars based in Greece, Italy and United States. Giannis Mountzios's co-authors include Meletios Α. Dimopoulos, Christos Papadimitriou, Jean‐Charles Soria, Evangelos Terpos, Panagiota Economopoulou, Dimitrios Pectasides, Solange Peters, Ramon Andrade de Mello, Aspasia Soultati and Amanda Psyrri and has published in prestigious journals such as Cell, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Giannis Mountzios

117 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment

2024 235 citations Giannis Mountzios, Solange Peters et al. profile →
Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE)

2021 138 citations Andrea Ferrari, Dan Stark et al. ESMO Open profile →
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges

2023 105 citations Giannis Mountzios, Jordi Remón et al. profile →

Peers

Countries citing papers authored by Giannis Mountzios

Since Specialization

Citations

This map shows the geographic impact of Giannis Mountzios's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giannis Mountzios with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giannis Mountzios more than expected).

Fields of papers citing papers by Giannis Mountzios

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Giannis Mountzios. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giannis Mountzios. The network helps show where Giannis Mountzios may publish in the future.

Co-authorship network of co-authors of Giannis Mountzios

This figure shows the co-authorship network connecting the top 25 collaborators of Giannis Mountzios. A scholar is included among the top collaborators of Giannis Mountzios based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giannis Mountzios. Giannis Mountzios is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	415P: Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: Insights from the pembrolizumab 5-year global registry 2025 ·Journal of Thoracic Oncology ·Alessio Cortellini, (unknown), (unknown), (unknown), (unknown), Sai Yendamuri, Eleni Karapanagiotou, Raffaele Giusti, (unknown), Michael Rost, Gabriele Minuti, Marcello Tiseo, Luca Cantini, Giannis Mountzios, (unknown), (unknown), Ahmed Nassar, (unknown), Carla Caruso, Valerio Guarrasi	0
2	De-Escalation Strategies With Immune Checkpoint Blockers in Non–Small Cell Lung Cancer: Do We Already Have Enough Evidence? 2025 ·Journal of Clinical Oncology ·Jordi Remón, (unknown), Paolo Bironzo, Francesco Cortiula, Jessica Menis, Mariana Brandão, Jarushka Naidoo, Robin M.J.M. van Geel, Noemı́ Reguart, Óscar Arrieta, Giannis Mountzios, Lizza Hendriks, Benjamin Besse	6
3	170P: Real-world (RW) characteristics, treatment (Tx) patterns and biomarker use in patients (pts) with early stage non-small cell lung cancer (ES NSCLC) in Greece: Results of the retrospective INFINITY study 2025 ·Journal of Thoracic Oncology ·Sofia Agelaki, Giannis Mountzios, Anna Koumarianou, (unknown), Helena Linardou, (unknown), (unknown), (unknown), Christos Emmanouilidis, P. Kosmidis, (unknown), D. Bafaloukos, (unknown), Davide Mauri, (unknown), (unknown), (unknown), (unknown), K. Syrigos	0
4	Beyond Chemoimmunotherapy in Advanced Non–Small Cell Lung Cancer: New Frontiers, New Challenges 2024 ·American Society of Clinical Oncology Educational Book ·Giannis Mountzios, Jarushka Naidoo, Chao Wang, Ben Creelan, (unknown), Toby C. Campbell, Solange Peters	14
5	Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies 2024 ·Cancers ·Pernelle Lavaud, (unknown), Lodovica Zullo, (unknown), Jarushka Naidoo, Giannis Mountzios, Olaf Mercier, Lizza Hendriks, Jordi Remón	9
6	Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study. 2024 ·Journal of Clinical Oncology ·Luis Paz‐Ares, Óscar Juan, Giannis Mountzios, Enriqueta Felip, Niels Reinmuth, Filippo de Marinis, Nicolas Girard, (unknown), Takayuki Takahama, Scott Owen, (unknown), Firas Badin, İrfan Çiçin, Sabeen Mekan, Riddhi Patel, Éric Zhang, (unknown), Marina Chiara Garassino	3
7	An assessment of the attitudes, knowledge, and education regarding the health care needs of LGBTQ patients with cancer: results of an ESMO/SIOPE global survey 2024 ·ESMO Open ·Emmanouil Saloustros, Andrea Ferrari, (unknown), Nathalie Gaspar, Giannis Mountzios, Anne Blondeel, Stefan Bielack, Dan Stark, Angela Toss, Katrin Scheinemann, S. Jezdic, Fedro A. Peccatori	1
8	1435P Clinical and molecular study with digital support of advanced non-small cell lung cancer patients: SNF-CLIMEDIN, a prospective randomized Hellenic Cooperative Oncology Group (HeCOG) study: Interim analysis 2023 ·Annals of Oncology ·Helena Linardou, (unknown), Kyriaki Papadopoulou, Nikolaos Korfiatis, Sofia Lampaki, Elena Fountzilas, Amanda Psyrri, Anastasios Vagionas, Athina Christopoulou, Epaminontas Samantas, Ilias Athanasiadis, Giannis Mountzios, Nikolaos Tsoukalas, Joseph Sgouros, Αngelos Koutras, (unknown), (unknown), George Fountzilas, P. Kosmidis	1
9	Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges 2023 ·Journal of Thoracic Oncology ·Jordi Remón, Stephanie P.L. Saw, Francesco Cortiula, Pawan Kumar Singh, Jessica Menis, Giannis Mountzios, Lizza Hendriks	17
10	Oral Toxicities in Cancer Patients, Who Receive Immunotherapy: A Case Series of 24 Patients 2023 ·SHILAP Revista de lepidopterología ·Ourania Nicolatou‐Galitis, Amanda Psyrri, Nikolaos Tsoukalas, (unknown), Helena Linardou, Dimitra Galiti, (unknown), (unknown), Evangelia Razis, (unknown), Nikolaos Kentepozidis, (unknown), (unknown), Efthymios Kyrodimos, Danai Daliani, G. P. Tsironis, Giannis Mountzios, Sofia Karageorgopoulou, (unknown), Konstantinos Syrigos	2
11	Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non–Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial 2023 ·Journal of Clinical Oncology ·Edward B. Garon, Shun Lü, Yasushi Goto, Pedro De Marchi, Luis Paz‐Ares, David R. Spigel, Michael Thomas, James Chih‐Hsin Yang, Andrea Ardizzoni, Fabrice Barlési, С. В. Орлов, Hiroshige Yoshioka, Giannis Mountzios, (unknown), Claudia Bossen, (unknown), Sabine Turri, Andrea P. Myers, Byoung Chul Cho	41
12	Spatial and Temporal Heterogeneity in Clonal Evolution of Nonsmall-cell Lung Cancer: Implications for Therapy 2022 ·SHILAP Revista de lepidopterología ·(unknown), Christos Tsagkaris, Giannis Mountzios	1
13	Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies 2022 ·Cancers ·(unknown), Christos Tsagkaris, Anna Chiara Corriero, Giulio Metro, Giannis Mountzios	50
14	Immunotherapy for the treatment of metastatic small cell lung cancer: Focus on pembrolizumab 2021 ·Expert Review of Clinical Pharmacology ·(unknown), Giannis Mountzios	1
15	A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The ‘LUNGFUL’ Study 2021 ·Cancers ·Giannis Mountzios, Anna Koumarianou, (unknown), Dimitriοs Mavroudis, E. Samantas, (unknown), Helena Linardou, (unknown), (unknown), Michalis V. Karamouzis, George Pentheroudakis, Sofia Lampaki, Μarios E. Froudarakis, (unknown), (unknown), (unknown), (unknown), (unknown), Konstantinos N. Syrigos	5
16	Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update 2019 ·Blood Advances ·Julia Bohlius, Kari Bohlke, Roberto Castelli, Benjamin Djulbegović, Maryam B. Lustberg, Massimo Martino, Giannis Mountzios, Namrata Peswani, Laura Porter, Tiffany Tanaka, Gianluca Trifirò, Hushan Yang, Alejandro Lazo‐Langner	112
17	Genotyping KRAS and EGFR Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for Treatment 2019 ·Cancer Genomics & Proteomics ·Helena Linardou, (unknown), G. Kouvatseas, Giannis Mountzios, Vasilios Karavasilis, E. Samantas, Anna Kalogera‐Fountzila, Despina Televantou, Kyriaki Papadopoulou, (unknown), (unknown), Thomas Zaramboukas, Ioannis Efstratiou, Sofia Lampaki, (unknown), (unknown), Konstantinos N. Syrigos, P. Kosmidis, Dimitrios Pectasides, George Fountzilas	11
18	Differential Expression of the Insulin-Like Growth Factor Receptor among Early Breast Cancer Subtypes 2014 ·PLoS ONE ·Giannis Mountzios, (unknown), Ioannis Kostopoulos, Helen P. Kourea, George Kouvatseas, Eleni Timotheadou, Pantelis Zebekakis, Ioannis Efstratiou, Helen Gogas, (unknown), Sofia Chrisafi, (unknown), George Pentheroudakis, Αngelos Koutras, Eleni Galani, Dimitrios Bafaloukos, George Fountzilas	15
19	Clinical Pharmacogenetics in Oncology: the Paradigm of Molecular Targeted Therapies 2010 ·Current Pharmaceutical Design ·Giannis Mountzios, Despina Sanoudou, Konstantinos N. Syrigos	6
20	Current and Emerging Roles of Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small Cell Lung Cancer 2010 ·Giannis Mountzios, Taofeek K. Owonikoko, Michalis V. Karamouzis, Athanassios Argiris	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact